Biomarkers Identification of Anti-tumor Necrosis Factor (TNF) α Agent's Efficacy in Ankylosing Spondylitis Patients
Status:
Completed
Trial end date:
2018-05-28
Target enrollment:
Participant gender:
Summary
To identify new candidate genes and proteins that are differentially expressed in responders'
vs non-responders to anti-TNF alpha therapy at the several time points the investigators will
use the transcriptomic and proteomic analyses. Demonstrate a link between gene expression and
protein markers regarding prediction to anti-TNF alpha therapy efficacy.